Krahel, J.A.;                     Baran, A.;                     Kamiński, T.W.;                     Maciaszek, M.;                     Flisiak, I.    
        Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J. Clin. Med. 2020, 9, 910.
    https://doi.org/10.3390/jcm9040910
    AMA Style
    
                                Krahel JA,                                 Baran A,                                 Kamiński TW,                                 Maciaszek M,                                 Flisiak I.        
                Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. Journal of Clinical Medicine. 2020; 9(4):910.
        https://doi.org/10.3390/jcm9040910
    
    Chicago/Turabian Style
    
                                Krahel, Julita Anna,                                 Anna Baran,                                 Tomasz W. Kamiński,                                 Magdalena Maciaszek,                                 and Iwona Flisiak.        
                2020. "Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data" Journal of Clinical Medicine 9, no. 4: 910.
        https://doi.org/10.3390/jcm9040910
    
    APA Style
    
                                Krahel, J. A.,                                 Baran, A.,                                 Kamiński, T. W.,                                 Maciaszek, M.,                                 & Flisiak, I.        
        
        (2020). Methotrexate Decreases the Level of PCSK9—A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. Journal of Clinical Medicine, 9(4), 910.
        https://doi.org/10.3390/jcm9040910